Celltrion biosim, eyeing Herceptin's megasales, measures up to the Roche med in phase 3

2nd June 2017 Uncategorised 0

Chasing biosim partners Mylan and Biocon for one of the top targets in the pharma industry, Celltrion reported Sunday that its version of Roche’s breast cancer med Herceptin stacked up to the reference blockbuster in a late-stage trial.

More: Celltrion biosim, eyeing Herceptin's megasales, measures up to the Roche med in phase 3
Source: fierce